United Therapeutics Corp. Hits New 52-Week High of $438.26

United Therapeutics Corp. has reached a significant milestone by hitting a new 52-week high of USD 438.26 on September 23, 2025. This achievement underscores the company's strong performance in the pharmaceuticals and biotechnology sector, where it operates as a mid-cap entity with a market capitalization of USD 28,352 million.
Over the past year, United Therapeutics has demonstrated impressive growth, with a 57.7% increase in stock price, significantly outperforming the S&P 500, which saw a gain of 17.38%. The company has maintained a robust return on equity (ROE) of 17.59%, reflecting high management efficiency and strong long-term fundamental strength.

Financial metrics indicate a solid position, with a price-to-earnings (P/E) ratio of 19.00 and a price-to-book ratio of 3.95. The company has also reported positive results for the last eight consecutive quarters, showcasing its operational strength with an operating cash flow of USD 1,368.6 million and an operating profit of USD 407.3 million. With a low debt-to-equity ratio of -0.42, United Therapeutics continues to solidify its standing in the market.